NASDAQ: TNXP Tonix Pharmaceuticals Holding Corp. 8-K

Tonix presents Phase 1 data for Lyme disease candidate TNX-4800, targets Phase 2 trial in H1 2027

Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read

3 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TNXP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 4:00 PM